MedWatch

CEO of Novo Nordisk on potential successors: "I've only just begun"

At the start of 2022, Lars Fruergaard Jørgensen enters his fifth year as CEO of Novo Nordisk. While talent is being nurtured in the organization, his successor might have a long time to wait.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH

The next-in-line to the throne of Denmark's most valuable company, Novo Nordisk, might not even have made it to the executive management level yet, says its current CEO, Lars Fruergaard Jørgensen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs